Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Persistent anti-Dra in two pregnancies.

N Rahimi-Levene1, A Kornberg, G Siegel

  • 1Blood Bank, Assaf-Harofeh Medical Center, Zerifin, Israel.

Immunohematology
|September 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.

ISRN hepatology·2016
Same author

Letter: prostaglandin E1 therapy with alprostadil and risk reduction of early hepatic cellular carcinoma after liver transplantation - authors' reply.

Alimentary pharmacology & therapeutics·2015
Same author

Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation.

Alimentary pharmacology & therapeutics·2015
Same author

Postinterventional tumor necrosis predicts recurrence-free long-term survival in liver transplant patients with advanced hepatocellular carcinoma.

Transplantation proceedings·2013
Same author

Niche-modulated and niche-modulating genes in bone marrow cells.

Blood cancer journal·2012
Same author

The increased expression of 14q32 small nucleolar RNA transcripts in promyelocytic leukemia cells is not dependent on PML-RARA fusion gene.

Blood cancer journal·2012
Same journal

Investigation of a neonate with blocked D phenomenon: resolving D type using serologic and molecular methods.

Immunohematology·2026
Same journal

Novel <i>JK*01</i> allele with c.299C>T p.(Thr100Ile) single nucleotide variant associated with loss of Jk<sup>a</sup> expression in two African American donors.

Immunohematology·2026
Same journal

An update on the GE (Gerbich) blood group system.

Immunohematology·2026
Same journal

Effect of long-term frozen storage on antibodies in blood samples: immunoglobulin, tetanus toxin antibody, and ABO antibody.

Immunohematology·2026
Same journal

To contributors to the 2025 issues.

Immunohematology·2026
Same journal

The Indian (IN 023) blood group system: an update.

Immunohematology·2026
See all related articles

A rare blood group antibody, anti-Drori (Dr(a)), was observed at high titers during two pregnancies. Despite high antibody levels, neither infant showed signs of hemolytic disease of the newborn, suggesting a unique protective mechanism.

Area of Science:

  • Immunology
  • Hematology
  • Genetics

Background:

  • The Drori (Dr(a)) antigen is a high-prevalence antigen on decay-accelerating factor (DAF, CD55) within the Cromer blood group system.
  • The Dr(a-) phenotype is rare, predominantly found in individuals of Jewish Bukhara or Japanese descent.
  • Cromer blood group system antibodies, including anti-Dr(a), have not been previously associated with hemolytic disease of the newborn (HDN).

Purpose of the Study:

  • To report a case of a woman with the Dr(a-) phenotype experiencing high anti-Dr(a) antibody titers during two pregnancies.
  • To investigate the clinical implications and potential mechanisms behind the observed high antibody titers in the absence of HDN.

Main Methods:

  • Case report detailing serological findings during two successive pregnancies.

Related Experiment Videos

  • Analysis of anti-Dr(a) antibody titers and direct antiglobulin test (DAT) results in mother and neonates.
  • Review of existing literature on Cromer blood group system antibodies and HDN.

    • Main Results:

    • The patient presented with high anti-Dr(a) antibody titers (256-512) in both pregnancies.
    • The first infant's red blood cells (RBCs) were DAT-negative, while the second infant's RBCs were DAT-positive at birth.
    • Neither infant exhibited clinical signs of HDN, despite the DAT-positive result in the second infant.

    Conclusions:

    • The high anti-Dr(a) titers observed in this case, coupled with the absence of HDN, challenge previous understanding of this antibody's clinical significance.
    • The findings suggest a potential mechanism, distinct from previously theorized placental adsorption, that protects against HDN in this specific context.
    • Further research is warranted to elucidate the protective factors and immunological mechanisms involved.